Skip to main content
AGEN
NASDAQ Life Sciences

Strategic Partner Zydus Acquires 5.9% Stake in Agenus at Significant Premium

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$3.4
Mkt Cap
$114.948M
52W Low
$1.38
52W High
$7.34
52W Position info
146% above low
Off High info
54% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

AGEN has more than doubled off its 52-week low of $1.38.

Summary

Zydus Lifesciences, a strategic collaborator, has acquired a 5.9% equity stake in Agenus Inc. for $16.0 million, purchasing shares at a substantial premium to the current market price.


Key Events · Ownership and Investor Activity · AGEN

  • Strategic Equity Investment

    Zydus Lifesciences acquired 2,133,333 shares of Agenus common stock, representing a 5.9% ownership stake, as part of a strategic collaboration.

  • Significant Premium Purchase

    The shares were purchased at $7.50 per share, totaling approximately $16.0 million, which is more than double the current stock price.

  • Part of Broader Collaboration

    This equity acquisition is a component of the strategic collaboration with Zydus, which also includes asset sales and licensing agreements for key oncology assets, as previously announced on January 16, 2026.

  • Board Representation Option

    Zydus has the option to appoint a board observer or member to Agenus's board of directors, signaling deeper strategic involvement.


Analysis · AGEN · Life Sciences

This Schedule 13D filing confirms the equity component of the recently announced strategic collaboration between Agenus and Zydus Lifesciences. The acquisition of a 5.9% stake for $16.0 million, particularly at a purchase price of $7.50 per share (a significant premium over the current market price), represents a strong vote of confidence from a strategic partner. This investment provides Agenus with substantial capital and further validates its assets and strategic direction, following the broader collaboration details disclosed on January 16, 2026. The option for Zydus to gain board representation underscores the depth of this partnership.

At the time of this filing, AGEN was trading at $3.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $114.9M. The 52-week trading range was $1.38 to $7.34. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AGEN - Latest Insights

AGEN
Jul 13, 2026, 6:43 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $3.95
Real-time Price: $6.60 info
Change: +$2.65 (+67%) info
Market Cap: $295.365M info
AGEN
Jul 13, 2026, 6:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.87
Real-time Price: $6.60 info
Change: +$2.73 (+71%) info
Market Cap: $295.365M info
AGEN
Jul 06, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.41
Real-time Price: $6.60 info
Change: +$3.19 (+94%) info
Market Cap: $295.365M info
AGEN
Jun 23, 2026, 10:14 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.15
Real-time Price: $6.60 info
Change: +$3.45 (+110%) info
Market Cap: $295.365M info
AGEN
May 15, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.48
Real-time Price: $6.60 info
Change: +$3.12 (+90%) info
Market Cap: $295.365M info